Seven Eight Capital’s MacroGenics MGNX Stock Holding History

Seven Eight Capital’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-13,341	Closed	-$372K	–	605
2020 Q2	$372K	Buy	+13,341	New	+$232K	0.27%	137

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Seven Eight Capital's MGNX Position: Q3 2020 in Review

Seven Eight Capital sold out of MacroGenics (MGNX) in Q3 2020, closing a stake of 13,341 shares — an estimated $372K sold.

Seven Eight Capital first reported a position in MGNX in Q2 2020 and held it in 1 quarter. The position peaked at $372K in Q2 2020. 139 funds tracked by Wall St. Rank hold MGNX as of Q3 2020.

Seven Eight Capital reported no remaining MacroGenics position as of Q3 2020 after selling out during the quarter.
Seven Eight Capital sold 13,341 MacroGenics shares in Q3 2020, an estimated $372K.
Seven Eight Capital first reported a position in MacroGenics in Q2 2020 and held it in 1 quarter.
Seven Eight Capital's MacroGenics position peaked at $372K in Q2 2020.
139 funds tracked by Wall St. Rank held MacroGenics as of Q3 2020.

Based on Seven Eight Capital's 13F filing for Q3 2020, filed 16 Nov 2020.